RT Journal Article
SR Electronic
T1 Untargeted saliva metabolomics reveals COVID-19 severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.06.21260080
DO 10.1101/2021.07.06.21260080
A1 Frampas, Cecile F.
A1 Longman, Katie
A1 Spick, Matt P.
A1 Lewis, Holly M.
A1 Costa, Catia D. S.
A1 Stewart, Alex
A1 Dunn-Walters, Deborah
A1 Greener, Danni
A1 Evetts, George E.
A1 Skene, Debra
A1 Trivedi, Drupad
A1 Pitt, Andrew R.
A1 Hollywood, Katherine
A1 Barran, Perdita
A1 Bailey, Melanie J.
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.07.06.21260080.abstract
AB Background The COVID-19 pandemic is likely to represent an ongoing global health issue given the potential for vaccine escape and the low likelihood of eliminating all reservoirs of the disease. Whilst diagnostic testing has progressed at pace, there is an unmet clinical need to develop tests that are prognostic, to triage the high volumes of patients arriving in hospital settings. Recent research has shown that serum metabolomics has potential for prognosis of disease progression. 1 In a hospital setting, collection of saliva samples is more convenient for both staff and patients, and therefore offers an alternative sampling matrix to serum. We demonstrate here for the first time that saliva metabolomics can reveal COVID-19 severity.Methods 88 saliva samples were collected from hospitalised patients with clinical suspicion of COVID-19, alongside clinical metadata. COVID-19 diagnosis was confirmed using RT-PCR testing. COVID severity was classified using clinical descriptors first proposed by SR Knight et al. Metabolites were extracted from saliva samples and analysed using liquid chromatography mass spectrometry.Results In this work, positive percent agreement of 1.00 between a PLS-DA metabolomics model and the clinical diagnosis of COVID severity was achieved. The negative percent agreement with the clinical severity diagnosis was also 1.00, for overall percent agreement of 1.00.Conclusions This research demonstrates that liquid chromatography-mass spectrometry can identify salivary biomarkers capable of separating high severity COVID-19 patients from low severity COVID-19 patients in a small cohort study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors would like to acknowledge funding from the EPSRC Impact Acceleration Account for sample collection and processing, as well as EPSRC Fellowship Funding EP/R031118/1, the University of Surrey and BBSRC BB/T002212/1. Mass Spectrometry was funded under EP/P001440/1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this project (IRAS project ID 155921) was obtained via the NHS Health Research Authority (REC reference: 14/LO/1221).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData related to this work will be stored and fully accessible on the MS Coalition open repository. The website URL is https://covid19-msc.org/COVID-19Coronavirus disease 19CRPC-reactive proteinHTNHypertensionIHDIschemic heart diseaseKEGGKyoto Encyclopedia of Genes and GenomesLCLiquid chromatographyLC-MSLiquid chromatography mass spectrometryLOOCVLeave-one-out cross validationMSMass spectrometryMS/MS or MS2Tandem mass spectrometryNPANegative percent agreementPCAPrincipal components analysisPCRPolymerase chain reactionPLS-DAPartial least squares-discriminant analysisPPAPositive percent agreementQCQuality controlRT-PCRReverse transcription polymerase chain reactionSARS-CoV-2Severe acute respiratory syndrome coronavirus 2T2DMType 2 diabetes mellitusVIPVariable importance in projection